BACKGROUND:

Nasal polyps by chronic rhinosinusitis are becoming more and more often in adults. Symptoms as nasal obstruction, rhinorrhea, loss of smell and more are present to the most of the patients. The ground reason is an eosinophilic inflammation. A biological treatment, mepolizumab, blocks the inflammatory pathway.

In our study we want to show the efficacy of mepoizumab in patients with chronic rhinosinusitis with nasal polyps

MATERIAL AND METHODS:

In our private office we have 5 patients (3 women and 2 men) aged 25 to 70 with CRSwNP. They all had undergone a FESS, 2 of them twice. The Sinonasal Outcome Test Score was varying from 62 to 87. They all had medical treatments in the past as steroid sprays and oral cortisone with moderate results without resolving the problem.

We used mepolizumab, 100mg subcutaneously every 4 weeks. Follow up was scheduled every 3, 6, 9 and 12 months. During the follow-up the endoscopy was documented and the patients filled the SNOT 22.

RESULTS:

All patients as soon as the first follow-up had reduced nasal polyps. SNOT was also reduced. 2 patients are in follow-up 1,5 year later, still with reduced symptoms.

CONCLUSION:

Mepolizumab improved nasal polyps" size, obstruction and loss of smell with no side effects. The treatment also reduces the risk of reccurence after operation.

References: Bachert C, Han JK, Wagenmann M, Backer V et al. EUFOREA expert board meeting on uncontrolled CRSwNP and biologics. Definition and management. J Allergy Clin Immunol 2021; 147 (1): 29-36

Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht